GEN Features Flagship Solutions, cTA Platform

Westminster, CO – November 8, 2018 — Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in Boston.

Dr. Joseph Krueger, Flagship Chief Science Officer, presented Flagship’s approach at the conference. Flagship’s cTA platform can help drug developers solve the key problems of variability, lack of precision, and insufficient clarity between test results and clinical outcome.

“By combining traditional IHC methods and stains with digital pathology approaches, our cTA platform can provide more precise data that can better predict contextual relationships between biomarker expression and treatment outcomes,” says Dr. Krueger.

For more detailed information about Flagship’s solutions, download Flagship’s white paper: Using Artificial Intelligence to Determine Patient Response to Immunotherapy.

Contact Flagship today to learn how we improve confidence in predicting contextual relationships between biomarker expression and treatment outcomes.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

Flagship Biosciences Is Honored with a Best Practices Award

We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...

Flagship Biosciences hires Tom Turi, Ph.D. as CSO

Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...